Jazz Pharmaceuticals Reports 7% Revenue Growth to $1.126 Billion in Q3 2025

Jazz Pharmaceuticals plc reported its financial results for the third quarter of 2025, revealing total revenues of $1.126 billion, a 7% increase from $1.055 billion in the same period last year. Product sales, which accounted for the majority of revenue, rose to $1.064 billion, up 8% year-over-year, driven primarily by strong sales of Xywav, which saw an 11% increase in sales to $431 million. However, the company experienced a significant decline in Xyrem sales, which fell by 39% to $35.7 million, attributed to increased competition from high-sodium oxybate products. For the nine months ending September 30, 2025, total revenues reached $3.070 billion, a 3% increase compared to $2.981 billion in the prior year.

Operating expenses surged to $1.069 billion for the quarter, a 34% increase from $795 million in Q3 2024. This rise was largely due to litigation settlements related to the Xyrem antitrust case and the Avadel litigation, which accounted for $61.5 million and $90 million, respectively. Research and development expenses remained relatively stable, decreasing slightly by 1% to $198 million, while selling, general, and administrative expenses rose significantly by 63% to $531 million, reflecting increased investment in commercial activities and integration costs from the recent acquisition of Chimerix.

The company reported a net income of $251 million for the third quarter, compared to $215 million in the same period last year. However, for the nine-month period, Jazz Pharmaceuticals recorded a net loss of $560 million, a stark contrast to a profit of $369 million in the prior year, primarily due to substantial expenses related to acquired in-process research and development and litigation settlements. The diluted earnings per share for the quarter were $4.08, up from $3.42 in Q3 2024.

In terms of strategic developments, Jazz Pharmaceuticals completed the acquisition of Chimerix in April 2025 for $944 million, which has expanded its oncology portfolio with the addition of Modeyso, a treatment for a rare brain tumor. The company also entered into a global license agreement with Saniona for the development of SAN2355, a preclinical candidate for epilepsy, further diversifying its pipeline. As of September 30, 2025, Jazz had approximately 15,675 patients using Xywav, including 10,725 for narcolepsy and 4,950 for idiopathic hypersomnia, indicating strong adoption of its products.

Looking ahead, Jazz Pharmaceuticals anticipates continued revenue growth driven by its commercial portfolio, particularly Xywav and Epidiolex, despite the challenges posed by competition and pricing pressures. The company remains focused on expanding its pipeline and leveraging its recent acquisitions to enhance its market position. However, it acknowledges the risks associated with maintaining sales levels amid increasing competition and regulatory scrutiny in the pharmaceutical industry.